Published in Cancer Weekly, September 6th, 2005
The technology was developed through joint collaboration between the scientific team of Power3 Medical and The University of Texas M. D. Anderson Cancer Center.
According to Dr. Ira L. Goldknopf, chief scientific officer and head of the scientific team at Power3, "By utilizing our very sensitive and reproducible proteomic methods with definitive patient samples, we discovered a series of proteins...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.